{"id":2853,"date":"2025-08-19T12:01:40","date_gmt":"2025-08-19T12:01:40","guid":{"rendered":"https:\/\/mmevost.wpenginepowered.com\/success-stories\/lifesome-therapeutics-nanobactair-cdti\/"},"modified":"2025-12-19T09:45:50","modified_gmt":"2025-12-19T09:45:50","slug":"lifesome-therapeutics-nanobactair-cdti","status":"publish","type":"success-stories","link":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/lifesome-therapeutics-nanobactair-cdti\/","title":{"rendered":"Lifesome Therapeutics- nanoBACTair"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"<p>Lifesome Therapeutics desarrolla Ohmline, un nanocarrier con actividad antimicrobiana para infecciones pulmonares, financiado con 488.000\u202f\u20ac del CDTI Multipais.<\/p>\n","protected":false},"featured_media":2520,"template":"","meta":{"_acf_changed":false},"flags":[61,65],"program":[42],"sector":[36],"class_list":["post-2853","success-stories","type-success-stories","status-publish","has-post-thumbnail","hentry","flags-pt","flags-es","program-programas-nacionales","sector-salud"],"acf":{"layouts_cases":[{"acf_fc_layout":"content","content":{"sections_settings":{"section_id":"","section_background":false,"section_padding":"base"},"content":"El proyecto de <a href=\"https:\/\/lifesometherapeutics.com\/\" target=\"_blank\" rel=\"noopener\"><b>Lifesome Therapeutics<\/b><\/a>, nanoBACTair, se enmarca en un contexto donde la resistencia a los antimicrobianos representa una amenaza sanitaria global, dificultando el tratamiento eficaz de infecciones bacterianas respiratorias y comprometiendo procedimientos como cirug\u00edas rutinarias, trasplantes y terapias oncol\u00f3gicas. El principal desaf\u00edo en el tratamiento de las infecciones respiratorias de origen bacteriano radica no solo en la aparici\u00f3n de cepas resistentes a antibi\u00f3ticos, sino tambi\u00e9n al limitado n\u00famero de agentes antibi\u00f3ticos disponibles, a su baja biodisponibilidad por su administraci\u00f3n oral o intravenosa, a los efectos secundarios adversos y a las propias barreras fisiol\u00f3gicas del organismo. Esto subraya la necesidad urgente de sistemas de liberaci\u00f3n de f\u00e1rmacos m\u00e1s eficientes, seguros y sostenibles.\r\n\r\nLa innovaci\u00f3n del proyecto reside en el desarrollo de <b>Ohmline<\/b>, un nanovector lip\u00eddico terap\u00e9utico con un dise\u00f1o \u00fanico que combina dos funciones: actuar como sistema de encapsulaci\u00f3n para la liberaci\u00f3n controlada de f\u00e1rmacos, y ejercer una actividad terap\u00e9utica antimicrobiana intr\u00ednseca que aumenta su eficacia. Esta tecnolog\u00eda permite la formulaci\u00f3n de nanopart\u00edculas con una excepcional variedad de antibi\u00f3ticos de diferente tama\u00f1o y solubilidad, como la ciprofloxacina, gentamicina o amoxicilina, logrando altos niveles de encapsulaci\u00f3n y eficacia terap\u00e9utica.\r\n\r\nEl proyecto cuenta con <a href=\"https:\/\/www.bac3gel.com\/\" target=\"_blank\" rel=\"noopener\">Bac3Gel<\/a>, que aporta su modelo 3D MU3GEL\u00ae para simular el entorno pulmonar y evaluar la eficacia de Ohmline. Ohmline tiene el potencial de transformar el tratamiento de infecciones respiratorias y extenderse a enfermedades inflamatorias o oncol\u00f3gicas. Su capacidad para mejorar la biodisponibilidad de los agentes terap\u00e9uticos, reducir efectos secundarios, aumentar su eficacia y combatir la resistencia bacteriana lo posiciona como una herramienta clave en medicina personalizada y salud p\u00fablica. En este contexto, el proyecto recibi\u00f3 en diciembre de 2024 una resoluci\u00f3n favorable de financiaci\u00f3n por parte del <a href=\"https:\/\/www.cdti.es\/en\" target=\"_blank\" rel=\"noopener\">CDTI<\/a>, en el marco del <a href=\"https:\/\/www.cdti.es\/ayudas\/proyectos-multi-pais\" target=\"_blank\" rel=\"noopener\"><b>programa \u201cMulti-Pa\u00eds\u201d<\/b><\/a> con una <b>subvenci\u00f3n de m\u00e1s de 488.000 \u20ac<\/b>, lo que impulsar\u00e1 su desarrollo y proyecci\u00f3n internacional en l\u00ednea con las prioridades estrat\u00e9gicas de la Uni\u00f3n Europea.\r\n\r\n<a class=\"sk-btn\" href=\"https:\/\/evolutioneurope.eu\/es\/blog\/innovation-interview-lifesome-therapeutics-cdti-multipais\/\" target=\"_blank\" rel=\"noopener\">Lee la entrevista con la Cofundadora de Lifesome Therapeutics<\/a>"}},{"acf_fc_layout":"media","media":{"sections_settings":{"section_id":"","section_background":false,"section_padding":"base"},"intro":"","section_type":"image","image":2518,"video_type":"mp4","upload_video":"","video_id":"","video_placeholder":"","video_title":"","button":null}}],"layouts":[{"acf_fc_layout":"quotes","quotes":{"quotes":[{"image":6410,"quote":"\"Destacamos la capacidad del equipo de Evolution para comunicarse con equipos internacionales y multidisciplinares, as\u00ed como para identificar posibles mejoras en los consorcios y en las tareas inicialmente planteadas.\"","image_mobile":6410,"author":"Ana Bouchet, Scientific Co-Founder, Lifesome Therapeutics","button":null}]}}]},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.5 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lifesome Therapeutics- nanoBACTair - evolution-europe<\/title>\n<meta name=\"description\" content=\"Lifesome Therapeutics desarrolla Ohmline, un nanocarrier con actividad antimicrobiana para infecciones pulmonares, financiado con 488.000\u202f\u20ac del CDTI Multipais.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/lifesome-therapeutics-nanobactair-cdti\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lifesome Therapeutics- nanoBACTair\" \/>\n<meta property=\"og:description\" content=\"Lifesome Therapeutics desarrolla Ohmline, un nanocarrier con actividad antimicrobiana para infecciones pulmonares, financiado con 488.000\u202f\u20ac del CDTI Multipais.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/lifesome-therapeutics-nanobactair-cdti\/\" \/>\n<meta property=\"og:site_name\" content=\"evolution-europe\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-19T09:45:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2025\/10\/LIFESOME-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"560\" \/>\n\t<meta property=\"og:image:height\" content=\"350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/lifesome-therapeutics-nanobactair-cdti\\\/\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/lifesome-therapeutics-nanobactair-cdti\\\/\",\"name\":\"Lifesome Therapeutics- nanoBACTair - evolution-europe\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/lifesome-therapeutics-nanobactair-cdti\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/lifesome-therapeutics-nanobactair-cdti\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/LIFESOME-.png\",\"datePublished\":\"2025-08-19T12:01:40+00:00\",\"dateModified\":\"2025-12-19T09:45:50+00:00\",\"description\":\"Lifesome Therapeutics desarrolla Ohmline, un nanocarrier con actividad antimicrobiana para infecciones pulmonares, financiado con 488.000\u202f\u20ac del CDTI Multipais.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/lifesome-therapeutics-nanobactair-cdti\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/lifesome-therapeutics-nanobactair-cdti\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/lifesome-therapeutics-nanobactair-cdti\\\/#primaryimage\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/LIFESOME-.png\",\"contentUrl\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/LIFESOME-.png\",\"width\":560,\"height\":350},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/lifesome-therapeutics-nanobactair-cdti\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Success stories\",\"item\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Lifesome Therapeutics- nanoBACTair\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/\",\"name\":\"evolution-europe\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#organization\",\"name\":\"Evolution Europe\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/social-share-image-2000x1600-1.jpg\",\"contentUrl\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/social-share-image-2000x1600-1.jpg\",\"width\":2000,\"height\":1600,\"caption\":\"Evolution Europe\"},\"image\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lifesome Therapeutics- nanoBACTair - evolution-europe","description":"Lifesome Therapeutics desarrolla Ohmline, un nanocarrier con actividad antimicrobiana para infecciones pulmonares, financiado con 488.000\u202f\u20ac del CDTI Multipais.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/lifesome-therapeutics-nanobactair-cdti\/","og_locale":"es_ES","og_type":"article","og_title":"Lifesome Therapeutics- nanoBACTair","og_description":"Lifesome Therapeutics desarrolla Ohmline, un nanocarrier con actividad antimicrobiana para infecciones pulmonares, financiado con 488.000\u202f\u20ac del CDTI Multipais.","og_url":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/lifesome-therapeutics-nanobactair-cdti\/","og_site_name":"evolution-europe","article_modified_time":"2025-12-19T09:45:50+00:00","og_image":[{"width":560,"height":350,"url":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2025\/10\/LIFESOME-.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/lifesome-therapeutics-nanobactair-cdti\/","url":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/lifesome-therapeutics-nanobactair-cdti\/","name":"Lifesome Therapeutics- nanoBACTair - evolution-europe","isPartOf":{"@id":"https:\/\/evolutioneurope.eu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/lifesome-therapeutics-nanobactair-cdti\/#primaryimage"},"image":{"@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/lifesome-therapeutics-nanobactair-cdti\/#primaryimage"},"thumbnailUrl":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2025\/10\/LIFESOME-.png","datePublished":"2025-08-19T12:01:40+00:00","dateModified":"2025-12-19T09:45:50+00:00","description":"Lifesome Therapeutics desarrolla Ohmline, un nanocarrier con actividad antimicrobiana para infecciones pulmonares, financiado con 488.000\u202f\u20ac del CDTI Multipais.","breadcrumb":{"@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/lifesome-therapeutics-nanobactair-cdti\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/lifesome-therapeutics-nanobactair-cdti\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/lifesome-therapeutics-nanobactair-cdti\/#primaryimage","url":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2025\/10\/LIFESOME-.png","contentUrl":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2025\/10\/LIFESOME-.png","width":560,"height":350},{"@type":"BreadcrumbList","@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/lifesome-therapeutics-nanobactair-cdti\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/evolutioneurope.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Success stories","item":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/"},{"@type":"ListItem","position":3,"name":"Lifesome Therapeutics- nanoBACTair"}]},{"@type":"WebSite","@id":"https:\/\/evolutioneurope.eu\/es\/#website","url":"https:\/\/evolutioneurope.eu\/es\/","name":"evolution-europe","description":"","publisher":{"@id":"https:\/\/evolutioneurope.eu\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/evolutioneurope.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/evolutioneurope.eu\/es\/#organization","name":"Evolution Europe","url":"https:\/\/evolutioneurope.eu\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/evolutioneurope.eu\/es\/#\/schema\/logo\/image\/","url":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2026\/04\/social-share-image-2000x1600-1.jpg","contentUrl":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2026\/04\/social-share-image-2000x1600-1.jpg","width":2000,"height":1600,"caption":"Evolution Europe"},"image":{"@id":"https:\/\/evolutioneurope.eu\/es\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/success-stories\/2853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/success-stories"}],"about":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/types\/success-stories"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/media\/2520"}],"wp:attachment":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/media?parent=2853"}],"wp:term":[{"taxonomy":"flags","embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/flags?post=2853"},{"taxonomy":"program","embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/program?post=2853"},{"taxonomy":"sector","embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/sector?post=2853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}